San Diego-primarily based Viking Therapeutics marked by itself as a significant competitor while in the weight loss drug industry in February immediately after revealing promising data from the mid-phase demo of experimental drug VK2735, which recommended it rivaled—and outperformed—Novo and Lilly drugs when provided for a weekly injection and